JFS Wealth Advisors’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

JFS Wealth Advisors’s Portfolio FRTX Stock Details FRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-22	Closed	-$22	–	2054
2023 Q3	$22	Hold	22	–	–	﹤0.01%	1954
2023 Q2	$16	Hold	22	–	–	﹤0.01%	1971
2023 Q1	$15	Hold	22	–	–	﹤0.01%	1948
2022 Q4	$33	Hold	22	–	–	﹤0.01%	1933
2022 Q3	$0	Hold	22	–	–	﹤0.01%	1969
2022 Q2	$0	Buy	+22	New	+$199	﹤0.01%	1983

Other funds holding FRTX

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

JFS Wealth Advisors's FRTX Position: Q4 2023 in Review

JFS Wealth Advisors sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2023, closing a stake of 22 shares — an estimated $22 sold.

JFS Wealth Advisors first reported a position in FRTX in Q2 2022 and held it in 6 quarters. The position peaked at $33 in Q4 2022. 1 fund tracked by Wall St. Rank holds FRTX as of Q4 2023.

JFS Wealth Advisors reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
JFS Wealth Advisors sold 22 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $22.
JFS Wealth Advisors first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2022 and held it in 6 quarters.
JFS Wealth Advisors's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $33 in Q4 2022.
1 fund tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2023.

Based on JFS Wealth Advisors's 13F filing for Q4 2023, filed 7 Feb 2024.